Top Page
Actinogen Medical
(Sydney:ACW)
Actinogen Medical (ACW) vs. iShares MSCI Australia ETF (EWA)
Actinogen Medical Business Overview & Revenue Model
Actinogen Medical Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.93M | 4.89M | 3.64M | 1.98M | 3.52M |
| Gross Profit | 9.93M | 4.48M | 3.24M | 1.60M | 3.10M |
| EBITDA | -12.92M | -15.22M | -12.72M | -5.35M | -8.20M |
| Net Income | -13.04M | -10.75M | -9.50M | -3.92M | -5.33M |
Balance Sheet | |||||
| Total Assets | 21.31M | 15.21M | 23.31M | 18.38M | 11.94M |
| Cash, Cash Equivalents and Short-Term Investments | 9.45M | 8.46M | 16.37M | 13.42M | 5.04M |
| Total Debt | 319.07K | 86.93K | 165.27K | 236.44K | 389.87K |
| Total Liabilities | 1.62M | 1.80M | 1.57M | 920.32K | 1.05M |
| Stockholders Equity | 19.70M | 13.41M | 21.74M | 17.46M | 10.89M |
Cash Flow | |||||
| Free Cash Flow | -16.96M | -8.73M | -9.52M | -1.73M | -2.88M |
| Operating Cash Flow | -16.95M | -8.70M | -9.52M | -1.72M | -2.86M |
| Investing Cash Flow | -8.16K | -36.60K | -2.94K | -6.19K | -22.76K |
| Financing Cash Flow | 17.95M | 824.62K | 12.42M | 10.11M | 282.26K |
Actinogen Medical Technical Analysis
Actinogen Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$116.52M | 12.01 | 45.86% | 1.61% | 71.65% | 152.89% | |
56 Neutral | AU$44.73M | ― | -49.72% | ― | ― | 10.78% | |
51 Neutral | $7.83B | -0.18 | -40.10% | 2.29% | 21.46% | -2.03% | |
48 Neutral | $101.60M | ― | -75.99% | ― | ― | 10.91% | |
| ― | $71.80M | ― | -154.88% | ― | ― | ― | |
40 Underperform | AU$105.25M | ― | -47.98% | ― | 700.00% | 26.88% | |
34 Underperform | AU$63.85M | ― | -108.26% | ― | ― | 53.41% |
Actinogen Medical Corporate Events
Actinogen Medical has reached a significant milestone in its XanaMIA phase 2b/3 clinical trial for Alzheimer’s disease, enrolling over 100 participants and planning an interim analysis in January 2026. Additionally, the company has secured a $13.8 million R&D tax incentive funding facility and completed a scale-up batch of Xanamem tablets, positioning itself for potential commercialization and partnerships.
Actinogen Medical announced the presentation of an academic poster at the Alzheimer’s Association International Conference in Toronto, showcasing the clinical validation of Xanamem’s activity in the brain. The poster highlights the positive clinical effects of Xanamem in lowering CNS cortisol in patients with major depressive disorder, supporting its potential as a treatment for brain diseases like Alzheimer’s and depression. The company also participated in the conference with a sponsored booth, providing an opportunity to engage with healthcare professionals and discuss their late-stage clinical program and advancements in dementia research.
Actinogen Medical has secured up to $13.8 million in non-dilutive funding through a Research and Development Tax Incentive, with an initial $3 million received and further amounts contingent on future approvals. This funding will support the ongoing XanaMIA phase 2b/3 Alzheimer’s disease trial and general working capital, strengthening the company’s financial position as it progresses toward key milestones, including interim analysis of its clinical trial.
Actinogen Medical has reached a significant milestone in its XanaMIA phase 2b/3 trial for Alzheimer’s disease by enrolling its 100th participant, setting the stage for an interim analysis of safety and efficacy data. This analysis, conducted by an independent Data Monitoring Committee, will occur in January 2026, with final trial results expected in late 2026. The trial aims to demonstrate the safety and efficacy of Xanamem, potentially expediting its regulatory approval. The company is also preparing for discussions with the US FDA regarding approval pathways and may seek commercial partnerships for the next phase of development.
Actinogen Medical Limited has announced that BVF Partners L.P., along with its affiliates, has ceased to be a substantial holder in the company. This development follows a series of on-market sales of fully paid ordinary shares by BVF Partners and its associates, which took place between April 22 and May 19, 2025. The divestment of shares by BVF Partners may impact Actinogen Medical’s shareholder composition and could influence market perceptions of the company’s stock.
Actinogen Medical announced positive results from a Phase 2 trial of its drug Xanamem, presented at the American Psychiatric Association’s 2025 meeting. The trial demonstrated that a 10 mg dose of Xanamem significantly improves symptoms of moderate Major Depressive Disorder, validating its mechanism of controlling brain cortisol levels. These findings not only highlight Xanamem’s potential as an effective antidepressant with a unique mechanism of action but also support its use in ongoing trials for Alzheimer’s Disease. The promising safety profile and durability of Xanamem’s benefits position it as a competitive candidate in the antidepressant market, potentially benefiting patients with Alzheimer’s who also suffer from depression.
Actinogen Medical announced a panel discussion featuring key company figures and experts to discuss advancements in Alzheimer’s treatments and the commercialization of Xanamem, their novel oral medication. The company is actively preparing for commercialization by designing pivotal trials, developing thought leaders, and refining communication strategies, which are crucial for maximizing future partnerships and addressing the significant unmet medical need for effective Alzheimer’s therapies.